Review



ldl c colorimetric assay kits  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology ldl c colorimetric assay kits
    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, <t>LDL-C,</t> triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.
    Ldl C Colorimetric Assay Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 106 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pmc13102662-76-48-53
    Average 95 stars, based on 106 article reviews
    ldl c colorimetric assay kits - by Bioz Stars, 2026-08
    95/100 stars

    Images

    1) Product Images from "Redistribution of branched-chain amino acid intake between active and inactive phases modulates hepatic metabolism in rats"

    Article Title: Redistribution of branched-chain amino acid intake between active and inactive phases modulates hepatic metabolism in rats

    Journal: Frontiers in Nutrition

    doi: 10.3389/fnut.2026.1754879

    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.
    Figure Legend Snippet: Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.

    Techniques Used: Clinical Proteomics, Western Blot, Staining, Phospho-proteomics



    Similar Products

    ldl c colorimetric assay kits  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology ldl c colorimetric assay kits
    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, <t>LDL-C,</t> triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.
    Ldl C Colorimetric Assay Kits, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pmc13102662-76-48-53
    Average 95 stars, based on 1 article reviews
    ldl c colorimetric assay kits - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    lowdensity lipoprotein cholesterol ldl c  (Elabscience Biotechnology)
    96
    Elabscience Biotechnology lowdensity lipoprotein cholesterol ldl c
    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, <t>LDL-C,</t> triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.
    Lowdensity Lipoprotein Cholesterol Ldl C, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Triglyceride+(TG)+Colorimetric+Assay+Kit+(Single+Reagent/pm41951010-83-20-33
    Average 96 stars, based on 1 article reviews
    lowdensity lipoprotein cholesterol ldl c - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    assay kit  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology assay kit
    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, <t>LDL-C,</t> triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.
    Assay Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pm41951010-83-27-33
    Average 95 stars, based on 1 article reviews
    assay kit - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    low density lipoprotein cholesterol ldl c  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology low density lipoprotein cholesterol ldl c
    Effects of GXNT on body weight and lipid metabolism of HFD-fed mice. (A) The animal experimental design; (B) Body weight in the sixth week; (C) Liver index; (D–G) Serum TC, TG, <t>LDL-C,</t> and HDL-C levels. # P < 0.05, ## P < 0.01 compared with the CON group; * P < 0.05, ** P < 0.01 compared with the MOD group.
    Low Density Lipoprotein Cholesterol Ldl C, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pmc13066125-120-15-36
    Average 95 stars, based on 1 article reviews
    low density lipoprotein cholesterol ldl c - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    low density lipoprotein cholesterol ldl c colorimetric assay kit  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology low density lipoprotein cholesterol ldl c colorimetric assay kit
    Effects of GXNT on body weight and lipid metabolism of HFD-fed mice. (A) The animal experimental design; (B) Body weight in the sixth week; (C) Liver index; (D–G) Serum TC, TG, <t>LDL-C,</t> and HDL-C levels. # P < 0.05, ## P < 0.01 compared with the CON group; * P < 0.05, ** P < 0.01 compared with the MOD group.
    Low Density Lipoprotein Cholesterol Ldl C Colorimetric Assay Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pmc13056780-7-0-8
    Average 95 stars, based on 1 article reviews
    low density lipoprotein cholesterol ldl c colorimetric assay kit - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    china a110 1 1 low density lipoprotein cholesterol ldl c colorimetric assay kit elabscience biotechnology co  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology china a110 1 1 low density lipoprotein cholesterol ldl c colorimetric assay kit elabscience biotechnology co
    Effects of GXNT on body weight and lipid metabolism of HFD-fed mice. (A) The animal experimental design; (B) Body weight in the sixth week; (C) Liver index; (D–G) Serum TC, TG, <t>LDL-C,</t> and HDL-C levels. # P < 0.05, ## P < 0.01 compared with the CON group; * P < 0.05, ** P < 0.01 compared with the MOD group.
    China A110 1 1 Low Density Lipoprotein Cholesterol Ldl C Colorimetric Assay Kit Elabscience Biotechnology Co, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/pm41886117-61-91-100
    Average 95 stars, based on 1 article reviews
    china a110 1 1 low density lipoprotein cholesterol ldl c colorimetric assay kit elabscience biotechnology co - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    plasma low density lipoprotein cholesterol ldl c  (Novus Biologicals)
    94
    Novus Biologicals plasma low density lipoprotein cholesterol ldl c
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Plasma Low Density Lipoprotein Cholesterol Ldl C, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/bio_rxiv__64898__2026__03__20__713290-247-0-12
    Average 94 stars, based on 1 article reviews
    plasma low density lipoprotein cholesterol ldl c - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    nbp3 25881  (Novus Biologicals)
    94
    Novus Biologicals nbp3 25881
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    Nbp3 25881, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol%2FLDL-C+Assay+Kit+(Colorimetric)/10__1113_slash_jp289326-91-28-31
    Average 94 stars, based on 1 article reviews
    nbp3 25881 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    e bc k205  (Elabscience Biotechnology)
    95
    Elabscience Biotechnology e bc k205
    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) <t>Circulating</t> <t>low-density</t> <t>lipoprotein</t> <t>cholesterol</t> <t>(LDL-C)</t> and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.
    E Bc K205, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ldl+c+colorimetric+assay+kits/Low-density+Lipoprotein+Cholesterol+(LDL-C)+Colorimetric+Assay+Kit/10__1016_slash_j__jneuroim__2026__578910-70-40-41
    Average 95 stars, based on 1 article reviews
    e bc k205 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.

    Journal: Frontiers in Nutrition

    Article Title: Redistribution of branched-chain amino acid intake between active and inactive phases modulates hepatic metabolism in rats

    doi: 10.3389/fnut.2026.1754879

    Figure Lengend Snippet: Experimental design, growth, intake partitioning, skeletal-muscle S6 signaling, and endpoint plasma markers under phase-shifted BCAA regimens. (A) Simplified study design: rats were maintained on a 12-h light:12-h dark cycle and assigned for 12 weeks to Ctrl (AIN-93G throughout), D + N − (BCAA+20 during the light/inactive phase and BCAA−20 during the dark/active phase), or D − N + (BCAA−20 during the light/inactive phase and BCAA+20 during the dark/active phase), where BCAA+20 and BCAA−20 denote diets containing ~20% higher or lower total BCAA content than Ctrl, respectively; daily energy and nitrogen were intended to be matched while allowing minor day-to-day variation during implementation ( n = 6/group). (B,C) Individual body weight trajectories from week 0 (acclimation) to weeks 1–12 (experimental period) (B) and weekly body weight distributions shown as boxplots (weeks 1–12) with pairwise between-group comparisons annotated above brackets (C) . (D,E) Representative immunoblots of total ribosomal protein S6 and phosphorylated S6 (p-S6, Ser235/236) in skeletal muscle at the end of the study, with total protein staining (TPS; Ponceau S) used for normalization ( n = 4/group; region approximately ~32 kDa displayed) (D) , and densitometric quantification of S6/TPS, p-S6/TPS, and phosphorylation ratio (p-S6/S6 computed as (p-S6/TPS)/(S6/TPS)) with individual animals overlaid (E) . (F) Weekly feed intake partitioned by circadian phase (inactive/light phase: 07:00–19:00; active/dark phase: 19:00–07:00); within each week, upper brackets/ p -values compare whole-day (24 h) total intake between the groups, and lower brackets/ p -values compare inactive vs. active intake within each group (red p-values indicate p < 0.05 as displayed). (G) Endpoint fasting plasma HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC), and malondialdehyde (MDA) across the groups (units as indicated on axes). Group colors follow Ctrl (red), D − N + (green), and D + N − (blue). Boxplots show median and interquartile range (IQR), whiskers extend to 1.5 × IQR, and points indicate individual values (with outliers beyond whiskers where shown). Pairwise statistics were computed using two-sided t-tests with Holm p -value adjustment.

    Article Snippet: Specifically, serum lipids were quantified by measuring total cholesterol (TC) using the Total Cholesterol (TC) Colorimetric Assay kits from Elabscience (Wuhan, China) (catalog no. E-BC-K109-M), high-density lipoprotein cholesterol (HDL-C) using the HDL-C Colorimetric Assay kits from Elabscience (Wuhan, China) (catalog no. E-BC-K221-M), low-density lipoprotein cholesterol (LDL-C) using the LDL-C Colorimetric Assay kits from Elabscience (Wuhan, China) (catalog no. E-BC-K205-M), malondialdehyde (MDA) using the Malondialdehyde (MDA) Colorimetric Assay kits from Elabscience (Wuhan, China) (catalog no. E-BC-K025-M), and triglycerides (TGs) using the Triglyceride (TG) Colorimetric Assay kits from Elabscience (Wuhan, China) (catalog no. E-BC-K261-M).

    Techniques: Clinical Proteomics, Western Blot, Staining, Phospho-proteomics

    Effects of GXNT on body weight and lipid metabolism of HFD-fed mice. (A) The animal experimental design; (B) Body weight in the sixth week; (C) Liver index; (D–G) Serum TC, TG, LDL-C, and HDL-C levels. # P < 0.05, ## P < 0.01 compared with the CON group; * P < 0.05, ** P < 0.01 compared with the MOD group.

    Journal: Frontiers in Pharmacology

    Article Title: Effects of Guanxinning tablet on the gut microbiota and bile acid metabolism in mice with hyperlipidemia

    doi: 10.3389/fphar.2026.1754769

    Figure Lengend Snippet: Effects of GXNT on body weight and lipid metabolism of HFD-fed mice. (A) The animal experimental design; (B) Body weight in the sixth week; (C) Liver index; (D–G) Serum TC, TG, LDL-C, and HDL-C levels. # P < 0.05, ## P < 0.01 compared with the CON group; * P < 0.05, ** P < 0.01 compared with the MOD group.

    Article Snippet: The levels of total cholesterol (TC) (E-BC-K109-M), triglycerides (TG) (E-BC-K251-M), high-density lipoprotein cholesterol (HDL-C) (E-BC-K221-M), low-density lipoprotein cholesterol (LDL-C) (E-BC-K205-M) and D-Lactic Acid (D-LA) (E-BC-K002-M) in the serum were measured using colorimetric assays using commercial kits (Elabscience, Wuhan, China).

    Techniques:

    (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Experimental workflow. Hepa1-6 mRNA (epi-editor, gene editor, or base editor) and sgRNA were formulated LUNAR ® for systemic delivery, while GalNAc-conjugated siRNA was administered directly. eGFP mRNA served as a vehicle control. Blood samples were collected at the indicated time points for downstream analyses. Created with BioRender.com. (B–C) Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels measured at each time point to assess hepatotoxicity. (D) Plasma PCSK9 protein levels quantified by ELISA. (E–F) Circulating low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. All plasma data (D–F) are normalized to eGFP control at the corresponding time point. Statistical analyses were performed as described in the Methods section. Error bars: SD.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Control, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

    (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Body weights of 8–12-week-old female C57BL/6N mice following intravenous administration of 1 mg/kg RNA formulated in LUNAR ® . (B–D) Plasma levels of PCSK9 protein (B), low-density lipoprotein cholesterol (LDL-C) (C), and total cholesterol (D) measured at indicated time points post-dosing. (E) Comparison of therapeutic efficacy of different gene-modifying modalities on plasma PCSK9, LDL-C, and total cholesterol levels at day 30 post-dose. Statistical significance was determined by one-way ANOVA with Tukey’s multiple comparisons test (* P < 0.05, *** P < 0.001). For PCSK9 comparisons, differences between groups not specifically indicated are all statistically significant ( P < 0.001). Error bars: SD.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Clinical Proteomics, Comparison, Drug discovery

    (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.

    Journal: bioRxiv

    Article Title: Targeted Epigenetic Modulation Outperforms Nuclease- and Deaminase-Based Editing for Durable Pcsk9 Silencing in a Clinically Relevant Delivery System

    doi: 10.64898/2026.03.20.713290

    Figure Lengend Snippet: (A) Experimental design comparing the efficacy of epi-editor delivery between the Capelluti et al. study and Arcturus Therapeutics. Plasma was collected at the indicated time points (dots colored by time). (B) Plasma PCSK9 levels measured at each time point post-dosing. Data were normalized to the respective vehicle controls (PBS-treated mice for Capelluti et al. and LUNAR ® -formulated eGFP mRNA for Arcturus data). (C–E) Comparison of plasma PCSK9 (C), LDL-C (D), and total cholesterol (E) at day 30 post-dosing. Values were normalized to the respective vehicle controls. Error bars: SD. Statistical significance was determined by one-way ANOVA followed by Tukey’s multiple comparisons test (* P < 0.05, ** P < 0.01, *** P < 0.001). Capelluti’s data were adapted from provided data in and Arcturus data were from the current study.

    Article Snippet: Plasma low-density lipoprotein cholesterol (LDL-C) was measured using a colorimetric assay kit (Novus Biologicals, Centennial, CO) following the manufacturer’s protocol, with samples loaded undiluted.

    Techniques: Clinical Proteomics, Comparison